What patent covers brensocatib (brensocatib hydrate), and who owns it?
I don’t have any provided information about brensocatib hydrate’s specific patents, patent numbers, assignees, or ownership. Without that, I can’t reliably identify the exact patent(s) covering brensocatib.
If you share a patent number, assignee name, a link to a patent record, or a jurisdiction (US/EU/WO/UK, etc.), I can help interpret what it covers (claims, active ingredients/formulations, indications, salts/hydrates, manufacturing, or methods of treatment) and summarize the likely practical impact.
When does the brensocatib hydrate patent expire?
Expiry depends on the jurisdiction and on what type of patent protection applies (basic drug substance vs. formulation vs. method-of-use), as well as any regulatory exclusivities. I don’t have the underlying patent metadata needed to compute or confirm a brensocatib expiry date.
Send the jurisdiction and the specific patent/publication number(s) and I can work out:
- the scheduled (nominal) expiration,
- whether term adjustments/extensions appear in the record,
- and how that interacts with exclusivities (if those are provided in your source).
Are there separate patents for the hydrate form vs. the active ingredient?
Many drug portfolios include different patent categories for the “drug substance” versus a specific salt/hydrate form (which can matter for claims and generic entry timing). But I can’t confirm whether brensocatib hydrate has form-specific patent claims based on your prompt alone.
If you provide the relevant patent claims or publication text, I can point out whether the protection is on:
- brensocatib itself (compound),
- a specific hydrate/crystal form,
- a pharmaceutical composition,
- or a method of treating a disease.
Can generics or biosimilars enter before brensocatib patent expiry?
Whether follow-on products can enter early depends on what is still protected at the time (compound/formulation/use) and whether regulators can approve a product that is designed to avoid infringement (e.g., non-infringing formulation/form/route). I can’t assess this for brensocatib without the actual patent list and claims.
If you share:
- the jurisdictions of interest (FDA/EMA, etc.),
- the patents you’ve found,
- and any regulatory milestones you have,
I can map the likely “blocked vs. potentially design-around” areas.
Where to find the authoritative brensocatib patent record (so you can verify)?
To answer “brensocatib hydrate patent” accurately, you typically need to look up:
- the patent publication(s) and assignee(s) in your target jurisdiction(s),
- and the regulatory exclusivity information that can affect market entry timing.
If you tell me which market you care about (US vs EU vs UK vs other), I can guide you on what to search for (e.g., “brensocatib,” “brensocatib hydrate,” salt/hydrate terms, and assignee names) and how to verify the publication-to-expiry linkage.
What I need from you to give a precise answer
Paste any one of the following and I’ll produce a specific patent-focused answer:
- patent number(s) or publication number(s),
- assignee/company name,
- jurisdiction (US/EPO/WO/UK, etc.),
- or a link to the patent database entry you’re using.
Sources: none provided.